Loading clinical trials...

Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia

Double-Blind, Follow-On Study of Pitavastatin (4 mg) Versus Atorvastatin (20 mg and 40 mg), With a Single-Blind Extension of Treatment, in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia

NCT00344370•Kowa Research Europe

View on ClinicalTrials.gov

Summary

This is a sixteen-week double-blind active-controlled follow-on and 28-week single-blind extension study for patients who participated in study NK-104-305.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Type II diabetes mellitus
•Combined dyslipidemia
•Completed NK-104-305 (NCT00309751)

Exclusion Criteria

•Withdrawal from NK-104-305 (NCT00309751)

Locations (35)

CCBR Aalborg

Aalborg, Denmark

CCBR A/S

Vejle, Denmark

CCBR Vejle

Vejle, Denmark

Gemeinschaftspraxis am Bahnhof

Berlin-Spandau, Germany

Pharmakologisches Studienzentum Chemnitz

Chemnitz, Germany

Internistische Diabetische Schwerpunktpraxis Dr.

Frankfurt am Main, Germany

Internistische Gemeinschaftspraxis

Mainz, Germany

Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler

Messkirch, Germany

Bhagwan Mahaveer Jain Heart Centre

Bangalore, India

Sri Ramachandra Medical College Hospital

Chennai, India

Key Dates

Start Date

August 1, 2006

Primary Completion Date

April 1, 2008

Completion Date

April 1, 2008

Last Updated

February 2, 2010

Enrollment

214

ACTUAL participants

Conditions

Type II Diabetes MellitusDyslipidemia

Interventions

Pitavastatin

DRUG

Atorvastatin

DRUG

A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors

NCT07238556

HypertensionDyslipidemia+3 more

View study

RECRUITINGNA

Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors

NCT07350694

Diabetes Type 2Type II Diabetes Mellitus

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 2, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia

Inclusion Criteria

Exclusion Criteria

A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors

Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers

Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D]

Wearable Devices Empowering Active Health Initiatives for High-Risk Stroke Populations